<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Coronavirus 2 (CoV)" exact="Severe" post="Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious"/>
 <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Coronavirus 2 (CoV) Severe" exact="Acute" post="Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic"/>
 <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Coronavirus 2 (CoV) Severe Acute" exact="Respiratory" post="Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia."/>
 <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Coronavirus 2 (CoV) Severe Acute Respiratory" exact="Syndrome" post="(SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses"/>
 <result pre="(CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly" exact="infectious" post="pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses"/>
 <result pre="range from those similar to the common cold to severe" exact="respiratory" post="syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the"/>
 <result pre="functional receptor. Measures are currently undertaken worldwide to control the" exact="infection" post="to avoid disruption of the social and economic equilibrium,"/>
 <result pre="preventive and treatment measures will at least contribute to contain" exact="viral" post="diffusion, attenuate activity, or even eliminate SARS-CoV2. In this"/>
 <result pre="neutralizing antibodies. A full spectrum of potential drugs for COVID-19" exact="infections" post="could in turn affect virus binding or enzymatic activities"/>
 <result pre="in turn affect virus binding or enzymatic activities involved in" exact="viral" post="replication and transcription. Furthermore, clinical trials are currently evaluating"/>
 <result pre="thus, CoV2 T cellsâ€™ frequency can be correlated with the" exact="disease" post="severity and outcome. Combinatorial antibody phage display may be"/>
 <result pre="to identify the immune repertoire of CoV2-specific neutralizing antibodies. SARS-CoV2" exact="infection" post="prevention treatment immune system outbreak 1. Introduction The 2019"/>
 <result pre="treatment immune system outbreak 1. Introduction The 2019 novel coronavirus" exact="disease" post="(COVID-19) is a highly infectious pneumonia recently recognized as"/>
 <result pre="Introduction The 2019 novel coronavirus disease (COVID-19) is a highly" exact="infectious" post="pneumonia recently recognized as â€œpandemicâ€� by the WHO [1]."/>
 <result pre="The 2019 novel coronavirus disease (COVID-19) is a highly infectious" exact="pneumonia" post="recently recognized as â€œpandemicâ€� by the WHO [1]. Mysterious"/>
 <result pre="recently recognized as â€œpandemicâ€� by the WHO [1]. Mysterious COVID-19" exact="pneumonia" post="was first reported in Wuhan, Hubei Province, China, in"/>
 <result pre="the world [1,2]. COVID-19 has been also named SARS (Severe" exact="Acute" post="Respiratory Syndrome)-Coronavirus (CoV)2 by the Coronavirus Study Group (CSG)"/>
 <result pre="world [1,2]. COVID-19 has been also named SARS (Severe Acute" exact="Respiratory" post="Syndrome)-Coronavirus (CoV)2 by the Coronavirus Study Group (CSG) of"/>
 <result pre="such as those similar to the common cold to severe/fatal" exact="respiratory" post="syndrome [1]. Chinese scientists isolated the virus from biological"/>
 <result pre="as those similar to the common cold to severe/fatal respiratory" exact="syndrome" post="[1]. Chinese scientists isolated the virus from biological samples"/>
 <result pre="nucleic acid sequence similarity with SARS-CoV and the Middle East" exact="Respiratory" post="Syndrome (MERS)-CoV. The crown-like morphology observed in electron microscopy"/>
 <result pre="acid sequence similarity with SARS-CoV and the Middle East Respiratory" exact="Syndrome" post="(MERS)-CoV. The crown-like morphology observed in electron microscopy specimens"/>
 <result pre="SARS-CoV and the Middle East Respiratory Syndrome (MERS)-CoV. The crown-like" exact="morphology" post="observed in electron microscopy specimens is due to the"/>
 <result pre="due to the presence of spike (S) glycoproteins on the" exact="viral" post="surface [6]. These proteins are constituted by an ectodomain"/>
 <result pre="cells. Instead, S2 contributes to fuse the host cellular and" exact="viral" post="membranes; thus, the viral nuclei acid can penetrate into"/>
 <result pre="to fuse the host cellular and viral membranes; thus, the" exact="viral" post="nuclei acid can penetrate into the host cells. The"/>
 <result pre="a functional receptor for SARS-CoV [7,8] (Figure 1). Furthermore, the" exact="viral" post="spike glycoproteins include a transmembrane anchor and a short"/>
 <result pre="the viral spike glycoproteins include a transmembrane anchor and a" exact="short" post="intracellular tail at C-terminal [5]. ACE2 is an exopeptidase"/>
 <result pre="addition to salivary droplets, other routes of transmission of the" exact="viral infection" post="are possible [6]. Indeed, recent studies provide morphological and/or"/>
 <result pre="to salivary droplets, other routes of transmission of the viral" exact="infection" post="are possible [6]. Indeed, recent studies provide morphological and/or"/>
 <result pre="Indeed, recent studies provide morphological and/or proteomic evidence of SARS-CoV2" exact="infection" post="and host-viral protein interaction from human colon epithelial (Caco-2),"/>
 <result pre="of SARS-CoV2 infection and host-viral protein interaction from human colon" exact="epithelial" post="(Caco-2), lung (A549-ACE2), monkey (Vero E6) kidney cell lines"/>
 <result pre="RNA copies/cell were detected in human autoptic samples from the" exact="respiratory" post="tract; lower levels were assayed in kidney, liver, heart,"/>
 <result pre="were detected in human autoptic samples from the respiratory tract;" exact="lower" post="levels were assayed in kidney, liver, heart, brain, and"/>
 <result pre="first described the epidemiological, clinical, and laboratory characteristics of COVID-19" exact="infectious" post="syndrome. From a pathogenetic point of view, the infection"/>
 <result pre="COVID-19 infectious syndrome. From a pathogenetic point of view, the" exact="infection" post="begins when the virus passes the nasal and larynx"/>
 <result pre="infection begins when the virus passes the nasal and larynx" exact="mucosa" post="to enter the respiratory tract and reach the lung."/>
 <result pre="virus passes the nasal and larynx mucosa to enter the" exact="respiratory" post="tract and reach the lung. Early symptoms include fever"/>
 <result pre="and cough [14]. From the lung, the virus enters the" exact="peripheral" post="blood, causing viremia and targeting organs that express ACE2,"/>
 <result pre="causing viremia and targeting organs that express ACE2, including the" exact="heart" post="and renal and gastrointestinal tract [14]. This explains why"/>
 <result pre="Usually 8 days occur from the symptomsâ€™ onset to the" exact="respiratory" post="syndrome, leading to exacerbation until 14 days from the"/>
 <result pre="syndrome, leading to exacerbation until 14 days from the onset." exact="Blood" post="cell counts in peripheral blood is normal or slightly"/>
 <result pre="until 14 days from the onset. Blood cell counts in" exact="peripheral" post="blood is normal or slightly low at the beginning,"/>
 <result pre="is normal or slightly low at the beginning, with eventual" exact="lymphopenia" post="[13]; this may affect antibody production. If in the"/>
 <result pre="lymphopenia [13]; this may affect antibody production. If in the" exact="acute" post="pneumonia phase, the immune system is effective, and the"/>
 <result pre="[13]; this may affect antibody production. If in the acute" exact="pneumonia" post="phase, the immune system is effective, and the patient"/>
 <result pre="occurs. Instead, if the patient is in advanced age, the" exact="disease" post="will become severe. Non-survivors were found to exhibit higher"/>
 <result pre="and there are no specific antiviral treatments to defeat COVID-19" exact="infection" post="in humans and other animal species [18,19,20,21]. Thus, it"/>
 <result pre="importance to identify and unravel treatments that may cure the" exact="disease" post="in infected subjects and eradicate it in affected populations."/>
 <result pre="infection. These include vaccine development based on definition of immunodominant" exact="viral" post="epitopes, passive immunization, several anti-viral therapeutics, and anti-inflammatories. We"/>
 <result pre="anti-inflammatories. We also highlight tools that may elucidate mechanisms governing" exact="viral infection" post="and clearance at the different stages of disease and"/>
 <result pre="We also highlight tools that may elucidate mechanisms governing viral" exact="infection" post="and clearance at the different stages of disease and"/>
 <result pre="governing viral infection and clearance at the different stages of" exact="disease" post="and advance effective immunotherapies based on monoclonal antibodies discovery."/>
 <result pre="today the gold standard for screening and diagnosis of COVID-19" exact="infection" post="in early stage, verifying its course, and estimating the"/>
 <result pre="bronchoalveolar lavage fluid, saliva, pharyngeal and nasal swabs, stool, or" exact="peripheral" post="blood [22,23]. Recently, as a novel nucleic acid amplification"/>
 <result pre="the use of four specially designed primers (complementary to a" exact="total" post="of six distinct sequences on target DNA) and of"/>
 <result pre="surveys in people suspected of current or previous SARS CoV2" exact="infection" post="through anti-viral IgG and IgM immunoglobulins testing. Accuracy of"/>
 <result pre="longer-time immunity, although it is the last to rise after" exact="infection" post="since positivity occurs between 13â€&quot;21 days. Reported time to"/>
 <result pre="to IgM positivity ranges from 5 to 10 days following" exact="disease" post="onset but declines soon after an infection is cleared"/>
 <result pre="10 days following disease onset but declines soon after an" exact="infection" post="is cleared [25]. Combining serology with PCR results can"/>
 <result pre="addition to low levels of serum albumin, increased values of" exact="total" post="bilirubin, creatinine, cardiac troponins, aspartate aminotransferase (AST), alanine aminotransferase"/>
 <result pre="significance [26]. Hematological parameters, such as leukocytosis, neutrophilia (indicative of" exact="bacterial" post="superinfection), and lymphopenia (indicative of reduced immune response to"/>
 <result pre="parameters, such as leukocytosis, neutrophilia (indicative of bacterial superinfection), and" exact="lymphopenia" post="(indicative of reduced immune response to the virus), are"/>
 <result pre="response to the virus), are predictors of progression toward severe" exact="respiratory" post="distress in COVID-19 infected people. Lippi et al. (2020)"/>
 <result pre="COVID-19 patients, especially with severe manifestations. As for severe and/or" exact="systemic" post="infectious diseases, consumption (disseminated) coagulopathy may be one of"/>
 <result pre="patients, especially with severe manifestations. As for severe and/or systemic" exact="infectious diseases," post="consumption (disseminated) coagulopathy may be one of the most"/>
 <result pre="with severe manifestations. As for severe and/or systemic infectious diseases," exact="consumption" post="(disseminated) coagulopathy may be one of the most severe"/>
 <result pre="manifestations. As for severe and/or systemic infectious diseases, consumption (disseminated)" exact="coagulopathy" post="may be one of the most severe complications of"/>
 <result pre="[30]. Indeed, a meta-analysis demonstrated significant reduction in mortality and" exact="viral" post="load, thus effectiveness of convalescent plasma (CP) immunotherapy for"/>
 <result pre="at high titers of neutralizing antibodies can likely reduce the" exact="viral" post="load and disease mortality. CP transfusion may affect COVID-19"/>
 <result pre="of neutralizing antibodies can likely reduce the viral load and" exact="disease" post="mortality. CP transfusion may affect COVID-19 pathogenesis through direct"/>
 <result pre="supportive care and anti-viral agents. In this initial trial, the" exact="primary" post="endpoint was to verify safety of CP infusion; the"/>
 <result pre="indeed, plasma was subjected to methylene blue photochemistry to inactivate" exact="residual" post="viral particles. Patients did not develop transfusion-related lung damage."/>
 <result pre="plasma was subjected to methylene blue photochemistry to inactivate residual" exact="viral" post="particles. Patients did not develop transfusion-related lung damage. Further,"/>
 <result pre="not develop transfusion-related lung damage. Further, there was no antibody-dependent" exact="infection" post="enhancement that may occur when subneutralizing concentrations of antibodies"/>
 <result pre="in China by recruiting patients with severe or life-threatening COVID-19" exact="syndrome" post="from 7 medical centers, CP therapy added to standard"/>
 <result pre="was started in Italy in March 2020 (NCT04321421), with the" exact="limited" post="recruitment of 43 patients [42]. On a general ground,"/>
 <result pre="follow precise ethical and controlled measures of selection, especially in" exact="absence of" post="knowledge of the basic biology of COVID-19, including its"/>
 <result pre="the infection. Generated mAbs can interrupt any stage of the" exact="viral" post="lifecycle or the host cell receptor proteins, thereby affecting"/>
 <result pre="Remdesivir is an experimental drug for the treatment of Ebola" exact="virus infection" post="that was effective for the treatment of MERS and"/>
 <result pre="is an experimental drug for the treatment of Ebola virus" exact="infection" post="that was effective for the treatment of MERS and"/>
 <result pre="the membrane of virally infected cells thus leading to block" exact="viral" post="replication and transcription. Transbodies have already being experimented for"/>
 <result pre="the treatment of other infections, including those caused by influenza," exact="hepatitis C," post="Ebola, and Dengue viruses [47]. The future use of"/>
 <result pre="infections, including those caused by influenza, hepatitis C, Ebola, and" exact="Dengue" post="viruses [47]. The future use of mAbs could overcome"/>
 <result pre="promising results obtained with mAbs in neutralizing SARS-CoV and MERS-CoV" exact="infections" post="their generation and subsequent large-scale production could be time"/>
 <result pre="respect to CP transfusion [44]. 3.2. Therapeutics Management of COVID-19" exact="infection" post="aims first to ameliorate clinical manifestations and to provide"/>
 <result pre="there is a full spectrum of potential drugs for COVID-19" exact="infections" post="that affects virus binding or enzymatic activities involved in"/>
 <result pre="infections that affects virus binding or enzymatic activities involved in" exact="viral" post="replication and transcription. Essential viral proteins may be target"/>
 <result pre="binding or enzymatic activities involved in viral replication and transcription." exact="Essential" post="viral proteins may be target of small molecule inhibitors"/>
 <result pre="or enzymatic activities involved in viral replication and transcription. Essential" exact="viral" post="proteins may be target of small molecule inhibitors i.e.,"/>
 <result pre="are ongoing with remdesivir, lopinavir, oseltamivir, darunavir, the HIV (Human" exact="Immunodeficiency" post="Virus) protease inhibitor ASC09F, ritonavir, and cobicistat [52]. There"/>
 <result pre="Chinese traditional medicine products already employed to treat other CoV" exact="infections" post="[16,53]. Of note, binding of the S1 COVID-19 protein"/>
 <result pre="and angiotensin type-1 receptor (AT1R) inhibitors are believed to reduce" exact="pulmonary" post="inflammation, thus reducing the mortality rate [16,54]. Remarkably, antiviral"/>
 <result pre="mortality rate [16,54]. Remarkably, antiviral drugs already experimented for CoV" exact="infections" post="can potentially treat COVID-19. The use of HIV protease"/>
 <result pre="Of note, cytokines play important roles in the immunopathology of" exact="viral" post="infections since innate immunity is the first line defense"/>
 <result pre="note, cytokines play important roles in the immunopathology of viral" exact="infections" post="since innate immunity is the first line defense against"/>
 <result pre="closely related to the development and progression of the Acute-Respiratory" exact="Disease" post="Syndrome (ARDS) or extrapulmonary multiorgan failure, leading to infection"/>
 <result pre="related to the development and progression of the Acute-Respiratory Disease" exact="Syndrome" post="(ARDS) or extrapulmonary multiorgan failure, leading to infection exacerbation"/>
 <result pre="Acute-Respiratory Disease Syndrome (ARDS) or extrapulmonary multiorgan failure, leading to" exact="infection" post="exacerbation or death. Therefore, immunomodulators and cytokine antagonists represent"/>
 <result pre="[57]. This drug is indicated for the treatment of severe" exact="chronic" post="inflammatory disorders, such as rheumatoid arthritis, systemic juvenile idiopathic"/>
 <result pre="for the treatment of severe chronic inflammatory disorders, such as" exact="rheumatoid arthritis," post="systemic juvenile idiopathic arthritis, and juvenile idiopathic polyarthritis [57]."/>
 <result pre="treatment of severe chronic inflammatory disorders, such as rheumatoid arthritis," exact="systemic" post="juvenile idiopathic arthritis, and juvenile idiopathic polyarthritis [57]. It"/>
 <result pre="of severe chronic inflammatory disorders, such as rheumatoid arthritis, systemic" exact="juvenile idiopathic arthritis," post="and juvenile idiopathic polyarthritis [57]. It also finds application"/>
 <result pre="disorders, such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and" exact="juvenile" post="idiopathic polyarthritis [57]. It also finds application for the"/>
 <result pre="application for the management of severe or life-threatening cytokine release" exact="syndrome" post="(CRS) that can be elicited by chimeric antigen receptor"/>
 <result pre="CRS treatment) in 21 patients with severe or critical COVID-19" exact="pneumonia" post="[58]. They observed reduction of oxygen requirement, resolution of"/>
 <result pre="a protocol for evaluating the efficacy of tocilizumab in treating" exact="respiratory" post="distress in COVID-19 patients (EudraCT Number 2020-001110-38) (Table 1)."/>
 <result pre="(EudraCT Number 2020-001110-38) (Table 1). Regarding the antiviral activity of" exact="Type 1" post="interferons (IFN-1), their beneficial effects are at an early"/>
 <result pre="administration may worsen the cytokine storm and exacerbate inflammation [59]." exact="Type 1" post="interferons designate a group of cytokines, including Î±, Î²,"/>
 <result pre="dendritic cells upon recognition by pattern recognition receptors (PRR). Since" exact="Type 1" post="interferons play a role in antiviral response and low"/>
 <result pre="IFN Î±-Î² have emerged as potentially effective drugs against CoV2." exact="Type 1" post="interferons are most often used in combination with other"/>
 <result pre="umifenovir) significantly reduced the duration of detectable virus in the" exact="upper" post="respiratory tract and the duration of elevated inflammatory markers."/>
 <result pre="significantly reduced the duration of detectable virus in the upper" exact="respiratory" post="tract and the duration of elevated inflammatory markers. The"/>
 <result pre="elevated inflammatory markers. The study had limitations, which are the" exact="absence of" post="a control group and the exclusive enrollment of moderate"/>
 <result pre="in combination with hydroxychloroquine and lopinavir/ritonavir was effective in reducing" exact="disease" post="symptoms at a low dose of 44 Î¼g administered"/>
 <result pre="have used steroids to control cytokine storm related to the" exact="infection" post="and occurrence of lung fibrosis. However, steroids have a"/>
 <result pre="control cytokine storm related to the infection and occurrence of" exact="lung fibrosis." post="However, steroids have a narrow therapeutic window since these"/>
 <result pre="Otherwise, virus replication and shedding and related symptoms of the" exact="infection" post="may exacerbate [59]. The utility of combined administration of"/>
 <result pre="suggested since infection, inflammation, and other factors may lead to" exact="disseminated intravascular coagulation" post="[14]. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used"/>
 <result pre="hydroxychloroquine (HCQ) have been used for prevention and treatment of" exact="malaria" post="[63]. They have immunomodulatory, rather than suppressive, characteristics that"/>
 <result pre="suppressive, characteristics that were revealed valid in the management of" exact="rheumatoid arthritis" post="and lupus erythematosus. These drugs apparently act by preventing"/>
 <result pre="characteristics that were revealed valid in the management of rheumatoid" exact="arthritis" post="and lupus erythematosus. These drugs apparently act by preventing"/>
 <result pre="were revealed valid in the management of rheumatoid arthritis and" exact="lupus erythematosus." post="These drugs apparently act by preventing antigen processing and"/>
 <result pre="by preventing antigen processing and presentation to the Major Histocompatibility" exact="Complex" post="(MHC) class II molecules due to increased pH and"/>
 <result pre="it blocks the TLR signaling cascade and the binding of" exact="cytosolic" post="DNA with cGAMP (cyclic guanosine monophosphateâ€&quot;adenosine monophosphate) synthase, thus"/>
 <result pre="of chloroquine or hydroxychloroquine in the treatment of COVID-19 associated" exact="pneumonia" post="[70]. Regarding potential side effects, CQ and HCQ are"/>
 <result pre="are not immunosuppressant; therefore, they are not without risk of" exact="infectious" post="complications. Both can produce gastrointestinal side effects of vomiting"/>
 <result pre="Long-term treatment with CQ and HCQ can produce retinopathy and" exact="cardiomyopathy" post="[71]. HCQ has a lower level of tissue accumulation;"/>
 <result pre="HCQ can produce retinopathy and cardiomyopathy [71]. HCQ has a" exact="lower" post="level of tissue accumulation; therefore, its usage is associated"/>
 <result pre="level of tissue accumulation; therefore, its usage is associated with" exact="lower" post="adverse effects [64]. Teicoplanin is another drug under investigation"/>
 <result pre="a glycopeptide antibiotic, currently used in the treatment of Gram-positive" exact="bacterial infection," post="especially in Staphylococcal infections. Already, this antibiotic showed antiviral"/>
 <result pre="antiviral activity in vitro against viruses, including Ebola, influenza, flavivirus," exact="hepatitis C," post="HIV, MERS-CoV, and SARS-CoV [72,73,74]. Teicoplanin would act on"/>
 <result pre="[72,73,74]. Teicoplanin would act on the early step of genomic" exact="viral" post="RNA release and the continuation of SARS-CoV2 life cycle"/>
 <result pre="from several concerns, which are not only control of the" exact="infection" post="in its spreading from its real geographical origin in"/>
 <result pre="this virus family [16]. S-protein-based vaccines should generate antibodies against" exact="viral" post="binding to ACE2 but also virus uncoating [49]. S-proteins"/>
 <result pre="attempted by using expression in virus-like particles (VLP), DNA, or" exact="viral" post="vectors [16,30,49,77,78,79]. It was suggested that the S1-receptor-binding domain"/>
 <result pre="models, especially electing small animals that closely resemble the clinical" exact="disease" post="caused by SARS-CoV2 infection in humans and its etiopathogenetic"/>
 <result pre="animals that closely resemble the clinical disease caused by SARS-CoV2" exact="infection" post="in humans and its etiopathogenetic mechanisms [16]. These are"/>
 <result pre="host cells, is apparently not affected by the presence or" exact="absence of" post="other structural viral proteins [16]. The immunity generated by"/>
 <result pre="not affected by the presence or absence of other structural" exact="viral" post="proteins [16]. The immunity generated by CoV2 vaccines is"/>
 <result pre="skewed Th2 immune response are considered ideal for controlling SARS-CoV2" exact="infection" post="since the generation of a skewed Th2 T cell"/>
 <result pre="doses (3 Î¼g and 6 Î¼g) to a macaque model," exact="partial" post="or complete protection was obtained; this was mediated by"/>
 <result pre="Î¼g and 6 Î¼g) to a macaque model, partial or" exact="complete" post="protection was obtained; this was mediated by humoral immunity"/>
 <result pre="immunity with controlled T cell responses to avoid immunopathology [85]." exact="Protein" post="subunit vaccines are produced in vitro by employing antigenic"/>
 <result pre="acid vaccines are currently under development for COVID-19 [83]. Recombinant" exact="viral" post="vector vaccines utilize the backbone from a genetically modified"/>
 <result pre="a genetically modified virus, such as adenoviruses, poxviruses, and Vesicular" exact="stomatitis" post="virus, having insertion sites for genes of the target"/>
 <result pre="A single vaccination was effective in rhesus macaques. A reduced" exact="viral" post="load was observed in bronchoalveolar lavage and respiratory tract"/>
 <result pre="A reduced viral load was observed in bronchoalveolar lavage and" exact="respiratory" post="tract of vaccinated animals respect to controls [86]. This"/>
 <result pre="involving 900 volunteers aged 18â€&quot;55 that received 5 Ã— 1010" exact="viral" post="particles (clinicaltrials.gov: NCT04324606). Vaccination with a lipid nanoparticle-encapsulated mRNA-1273"/>
 <result pre="mRNA-1273 encoding SARS-CoV2 S-protein developed by Moderna (NCT042283461) [83,85] prevented" exact="viral" post="replication in the lungs of mice challenged with CoV2."/>
 <result pre="trials are currently ongoing (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine/, accessed on June 2020). Adenovirus" exact="type 5" post="vector expressing S-protein (Ad5-nCoV) from CanSino Biological (NCT04313127) is"/>
 <result pre="in Phase I. Participants with pre-existing Ad5 neutralizing antibodies exhibited" exact="lower" post="humoral and cellular responses. BNT162 (produced by BioNTech, Mainz,"/>
 <result pre="vector expressing a synthetic minigene based on parts of selected" exact="viral" post="proteins (pathogen-specific aAPC, Phase I, NCT04299724). 5. Conclusions SARS-CoV2"/>
 <result pre="anti-inflammatory drugs, such as tocilizumab, at early stage of the" exact="infection" post="for timely control of the disease and to avoid"/>
 <result pre="early stage of the infection for timely control of the" exact="disease" post="and to avoid the risk of mortality. Modern technologies"/>
 <result pre="in a near future to validate vaccination strategies in eradicating" exact="viral infection" post="from humans. In this regard, reverse vaccinology based on"/>
 <result pre="a near future to validate vaccination strategies in eradicating viral" exact="infection" post="from humans. In this regard, reverse vaccinology based on"/>
 <result pre="preclinical efficacy due to generated humoral T cell and reduced" exact="viral" post="load responses are already available. Development and optimization of"/>
 <result pre="CD4+ T cell responses and eventually correlate their frequency with" exact="disease" post="severity and outcome. This may open the pathway to"/>
 <result pre="immune repertoire of SARS-CoV2-specific neutralizing antibodies. As suggested for other" exact="viral" post="infections [93], this approach may lead to elucidate mechanisms"/>
 <result pre="repertoire of SARS-CoV2-specific neutralizing antibodies. As suggested for other viral" exact="infections" post="[93], this approach may lead to elucidate mechanisms governing"/>
 <result pre="infections [93], this approach may lead to elucidate mechanisms governing" exact="viral infection" post="and clearance at the different stages of disease and"/>
 <result pre="[93], this approach may lead to elucidate mechanisms governing viral" exact="infection" post="and clearance at the different stages of disease and"/>
 <result pre="governing viral infection and clearance at the different stages of" exact="disease" post="and advance effective immunotherapies based on monoclonal antibodies discovery."/>
 <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="Enzyme 2 Ad5 Adenovirus 5 ALT Alanine aminotransferase ARDS Acute-respiratory" exact="disease" post="syndrome AST Aspartate aminotransferase AT1R Angiotensin type-1 receptor CAR"/>
 <result pre="2 Ad5 Adenovirus 5 ALT Alanine aminotransferase ARDS Acute-respiratory disease" exact="syndrome" post="AST Aspartate aminotransferase AT1R Angiotensin type-1 receptor CAR Chimeric"/>
 <result pre="Angiotensin type-1 receptor CAR Chimeric antigen receptor CEPI Coalition for" exact="Epidemic" post="Preparedness Innovations cGAMP Cyclic guanosine monophosphateâ€&quot;adenosine monophosphate CoV Coronavirus"/>
 <result pre="Innovations cGAMP Cyclic guanosine monophosphateâ€&quot;adenosine monophosphate CoV Coronavirus COVID-19 Coronavirus" exact="disease" post="2019 CP Convalescent plasma CQ Chloroquine CRP C reactive"/>
 <result pre="plasma CQ Chloroquine CRP C reactive protein CRS Cytokine release" exact="syndrome" post="CTL Cytotoxic T lymphocytes DCs Dendritic cells ESR Erythrocyte"/>
 <result pre="Erythrocyte sedimentation rate hAds Human adenoviruses HCQ Hydroxychloroquine HIV Human" exact="Immunodeficiency" post="Virus IDV Immune-derived vaccines iPSC Induced pluripotent stem cells"/>
 <result pre="dehydrogenase LMWH Low molecular weight heparin mAbs Monoclonal antibodies MDW" exact="Monocyte" post="volume distribution width MERS Middle East Respiratory Syndrome MHC"/>
 <result pre="Monoclonal antibodies MDW Monocyte volume distribution width MERS Middle East" exact="Respiratory" post="Syndrome MHC Major Histocompatibility Complex PRR Pattern Recognition Receptors"/>
 <result pre="antibodies MDW Monocyte volume distribution width MERS Middle East Respiratory" exact="Syndrome" post="MHC Major Histocompatibility Complex PRR Pattern Recognition Receptors PT"/>
 <result pre="distribution width MERS Middle East Respiratory Syndrome MHC Major Histocompatibility" exact="Complex" post="PRR Pattern Recognition Receptors PT Prothrombin time RAS Reninâ€&quot;angiotensin"/>
 <result pre="domain RdRp RNA-dependent RNA polymerase rRT-PCR Reverse real-time PCR SARS" exact="Severe" post="Acute Respiratory Syndrome sdAb Single-domain antibodies siRNAs Anti-sense RNA"/>
 <result pre="RdRp RNA-dependent RNA polymerase rRT-PCR Reverse real-time PCR SARS Severe" exact="Acute" post="Respiratory Syndrome sdAb Single-domain antibodies siRNAs Anti-sense RNA TLR"/>
 <result pre="RNA-dependent RNA polymerase rRT-PCR Reverse real-time PCR SARS Severe Acute" exact="Respiratory" post="Syndrome sdAb Single-domain antibodies siRNAs Anti-sense RNA TLR Toll"/>
 <result pre="RNA polymerase rRT-PCR Reverse real-time PCR SARS Severe Acute Respiratory" exact="Syndrome" post="sdAb Single-domain antibodies siRNAs Anti-sense RNA TLR Toll like"/>
 <result pre="global health concernLancet202039547047310.1016/S0140-6736(20)30185-931986257 2.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 3.FehrA.R.PerlmanS.Coronaviruses: An Overview"/>
 <result pre="Med.202038272773310.1056/NEJMoa200101731978945 3.FehrA.R.PerlmanS.Coronaviruses: An Overview of Their Replication and PathogenesisRecent Results" exact="Cancer" post="Res.2015128212310.1007/978-1-4939-2438-7_1 4.ChanJ.F.-W.KokK.-H.ZhuZ.ChuH.ToK.K.-W.YuanS.YuenK.-Y.Genomic characterization of the 2019 novel human-pathogenic coronavirus"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 5.LiF.Structure, Function, and Evolution"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microbes Infect.2020922123610.1080/22221751.2020.171990231987001 5.LiF.Structure, Function, and Evolution"/>
 <result pre="9.BouhaddouM.MemonD.MeyerB.WhiteK.M.RezeljV.V.MarreroM.C.PolaccoB.J.MelnykJ.E.UlfertsS.KaakeR.M.et al.The Global Phosphorylation Landscape of SARS-CoV-2 InfectionCell202010.1016/j.cell.2020.06.034 10.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 11.PuellesV.G.LÃ¼tgehetmannM.LindenmeyerM.T.SperhakeJ.P.WongM.N.AllweissL.ChillaS.HeinemannA.WannerN.LiuS.et al.Multiorgan and Renal Tropism"/>
 <result pre="10.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell infection and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 11.PuellesV.G.LÃ¼tgehetmannM.LindenmeyerM.T.SperhakeJ.P.WongM.N.AllweissL.ChillaS.HeinemannA.WannerN.LiuS.et al.Multiorgan and" exact="Renal" post="Tropism of SARS-CoV-2N. Engl. J. Med.202010.1056/NEJMc201140032402155 12.SharmaA.GarciaG.WangY.PlummerJ.T.MorizonoK.ArumugaswamiV.SvendsenC.N.Human iPSC-Derived Cardiomyocytes,"/>
 <result pre="al.Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirusâ€&quot;Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA2020323106110.1001/jama.2020.158532031570 14.LinL.LuL.CaoW.LiT.Hypothesis for potential pathogenesis of SARS-CoV-2"/>
 <result pre="of SARS-CoV-2 infectionâ€&quot;a review of immune changes in patients with" exact="viral" post="pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 15.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.et al.Clinical Characteristics of Coronavirus Disease"/>
 <result pre="with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 15.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.et al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 16.DhamaK.SharunK.TiwariR.DadarM.MalikY.S.SinghK.P.ChaicumpaW.COVID-19, an emerging"/>
 <result pre="vaccines, immunotherapeutics, and therapeuticsHum. Vaccines Immunother.2020161232123810.1080/21645515.2020.173522732186952 17.JiangS.DuL.ShiZ.An emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: Calling for developing therapeutic and"/>
 <result pre="Lab. Med.2020581131113410.1515/cclm-2020-019832119647 27.LippiG.PlebaniM.The critical role of laboratory medicine during coronavirus" exact="disease" post="2019 (COVID-19) and other viral outbreaksClin. Chem. Lab. Med.2020581063106910.1515/cclm-2020-024032191623"/>
 <result pre="of laboratory medicine during coronavirus disease 2019 (COVID-19) and other" exact="viral" post="outbreaksClin. Chem. Lab. Med.2020581063106910.1515/cclm-2020-024032191623 28.HanH.YangL.LiuR.LiuF.WuK.-L.LiJ.LiuX.-H.ZhuC.Prominent changes in blood coagulation"/>
 <result pre="coagulation of patients with SARS-CoV-2 infectionClin. Chem. Lab. Med.2020581116112010.1515/cclm-2020-018832172226 29.SimmonsJ.W.PittetJ.-F.The" exact="coagulopathy" post="of acute sepsisCurr. Opin. Anaesthesiol.20152822723610.1097/ACO.000000000000016325590467 30.YangZ.-Y.KongW.-P.HuangY.RobertsA.MurphyB.R.SubbaraoK.NabelG.J.A DNA vaccine induces"/>
 <result pre="patients with SARS-CoV-2 infectionClin. Chem. Lab. Med.2020581116112010.1515/cclm-2020-018832172226 29.SimmonsJ.W.PittetJ.-F.The coagulopathy of" exact="acute" post="sepsisCurr. Opin. Anaesthesiol.20152822723610.1097/ACO.000000000000016325590467 30.YangZ.-Y.KongW.-P.HuangY.RobertsA.MurphyB.R.SubbaraoK.NabelG.J.A DNA vaccine induces SARS coronavirus"/>
 <result pre="of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of" exact="Severe" post="Acute Respiratory Infections of Viral Etiology: A Systematic Review"/>
 <result pre="Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe" exact="Acute" post="Respiratory Infections of Viral Etiology: A Systematic Review and"/>
 <result pre="Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute" exact="Respiratory" post="Infections of Viral Etiology: A Systematic Review and Exploratory"/>
 <result pre="and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory" exact="Infections" post="of Viral Etiology: A Systematic Review and Exploratory Meta-analysisJ."/>
 <result pre="Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of" exact="Viral" post="Etiology: A Systematic Review and Exploratory Meta-analysisJ. Infect. Dis.2014211809010.1093/infdis/jiu39625030060"/>
 <result pre="38.ZhangB.LiuS.TanT.HuangW.DongY.ChenL.ChenQ.ZhangL.ZhongQ.ZhangX.et al.Treatment With Convalescent Plasma for Critically Ill Patients With" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 InfectionChest2020158e9e1310.1016/j.chest.2020.03.03932243945 39.SalazarE.PerezK.K.AshrafM.ChenJ.CastilloB.ChristensenP.A.EubankT.BernardD.W.EagarT.N.LongS.W.et al.Treatment of"/>
 <result pre="al.Treatment With Convalescent Plasma for Critically Ill Patients With Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 InfectionChest2020158e9e1310.1016/j.chest.2020.03.03932243945 39.SalazarE.PerezK.K.AshrafM.ChenJ.CastilloB.ChristensenP.A.EubankT.BernardD.W.EagarT.N.LongS.W.et al.Treatment of Coronavirus"/>
 <result pre="With Convalescent Plasma for Critically Ill Patients With Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 InfectionChest2020158e9e1310.1016/j.chest.2020.03.03932243945 39.SalazarE.PerezK.K.AshrafM.ChenJ.CastilloB.ChristensenP.A.EubankT.BernardD.W.EagarT.N.LongS.W.et al.Treatment of Coronavirus Disease"/>
 <result pre="Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 InfectionChest2020158e9e1310.1016/j.chest.2020.03.03932243945 39.SalazarE.PerezK.K.AshrafM.ChenJ.CastilloB.ChristensenP.A.EubankT.BernardD.W.EagarT.N.LongS.W.et al.Treatment of Coronavirus Disease 2019"/>
 <result pre="Acute Respiratory Syndrome Coronavirus 2 InfectionChest2020158e9e1310.1016/j.chest.2020.03.03932243945 39.SalazarE.PerezK.K.AshrafM.ChenJ.CastilloB.ChristensenP.A.EubankT.BernardD.W.EagarT.N.LongS.W.et al.Treatment of Coronavirus" exact="Disease" post="2019 (COVID-19) Patients with Convalescent PlasmaAm. J. Pathol.202010.1016/j.ajpath.2020.05.014 40.LiL.ZhangW.HuY.TongX.ZhengS.YangJ.KongY.RenL.WeiQ.MeiH.et"/>
 <result pre="Plasma Therapy on Time to Clinical Improvement in Patients With" exact="Severe" post="and Life-threatening COVID-19JAMA202010.1001/jama.2020.10044 41.EckhardtC.M.CummingsM.J.RajagopalanK.N.BordenS.BitanZ.C.WolfA.KantorA.BrieseT.MeyerB.J.JacobsonS.D.et al.Evaluating the efficacy and safety"/>
 <result pre="transcription and innate immune antagonismEmerg. Microbes Infect.2018711510.1038/s41426-018-0031-329323102 48.AdedejiA.O.SeversonW.JonssonC.B.SinghK.WeissS.R.SarafianosS.G.Novel Inhibitors of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Entry That Act by Three"/>
 <result pre="and innate immune antagonismEmerg. Microbes Infect.2018711510.1038/s41426-018-0031-329323102 48.AdedejiA.O.SeversonW.JonssonC.B.SinghK.WeissS.R.SarafianosS.G.Novel Inhibitors of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Entry That Act by Three Distinct"/>
 <result pre="innate immune antagonismEmerg. Microbes Infect.2018711510.1038/s41426-018-0031-329323102 48.AdedejiA.O.SeversonW.JonssonC.B.SinghK.WeissS.R.SarafianosS.G.Novel Inhibitors of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Entry That Act by Three Distinct MechanismsJ."/>
 <result pre="immune antagonismEmerg. Microbes Infect.2018711510.1038/s41426-018-0031-329323102 48.AdedejiA.O.SeversonW.JonssonC.B.SinghK.WeissS.R.SarafianosS.G.Novel Inhibitors of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Entry That Act by Three Distinct MechanismsJ. Virol.2013878017802810.1128/JVI.00998-1323678171"/>
 <result pre="from the Past: Possible Urgent Prevention and Treatment Options for" exact="Severe" post="Acute Respiratory Infections Caused by 2019-nCoVChemBioChem20202173073810.1002/cbic.20200004732022370 52.LiG.De ClercqE.Therapeutic options"/>
 <result pre="the Past: Possible Urgent Prevention and Treatment Options for Severe" exact="Acute" post="Respiratory Infections Caused by 2019-nCoVChemBioChem20202173073810.1002/cbic.20200004732022370 52.LiG.De ClercqE.Therapeutic options for"/>
 <result pre="Past: Possible Urgent Prevention and Treatment Options for Severe Acute" exact="Respiratory" post="Infections Caused by 2019-nCoVChemBioChem20202173073810.1002/cbic.20200004732022370 52.LiG.De ClercqE.Therapeutic options for the"/>
 <result pre="Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory" exact="Infections" post="Caused by 2019-nCoVChemBioChem20202173073810.1002/cbic.20200004732022370 52.LiG.De ClercqE.Therapeutic options for the 2019"/>
 <result pre="Discov.20201914915010.1038/d41573-020-00016-032127666 53.LuoH.TangQ.-L.ShangY.-X.LiangS.-B.YangM.RobinsonN.LiuJ.-P.Can Chinese Medicine Be Used for Prevention of Corona" exact="Virus Disease" post="2019 (COVID-19)? A Review of Historical Classics, Research Evidence"/>
 <result pre="53.LuoH.TangQ.-L.ShangY.-X.LiangS.-B.YangM.RobinsonN.LiuJ.-P.Can Chinese Medicine Be Used for Prevention of Corona Virus" exact="Disease" post="2019 (COVID-19)? A Review of Historical Classics, Research Evidence"/>
 <result pre="Med.20203821851185210.1056/NEJMe200547732187463 56.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavirâ€&quot;Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 57.BiggioggeroM.CrottiC.BeccioliniA.FavalliE.Tocilizumab in the treatment of"/>
 <result pre="trialInt. Immunopharmacol.20208510668810.1016/j.intimp.2020.10668832544867 63.YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.NingyiJ.JiangC.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res.20122330030210.1038/cr.2012.16523208422"/>
 <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res.20122330030210.1038/cr.2012.16523208422 64.ZhouD.DaiS.-M.TongQ.COVID-19: A recommendation to"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.20122330030210.1038/cr.2012.16523208422 64.ZhouD.DaiS.-M.TongQ.COVID-19: A recommendation to"/>
 <result pre="A recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ. Antimicrob. Chemother.2020751667167010.1093/jac/dkaa11432196083 65.BorneB.E.V.D.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and hydroxychloroquine"/>
 <result pre="progressionJ. Antimicrob. Chemother.2020751667167010.1093/jac/dkaa11432196083 65.BorneB.E.V.D.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and hydroxychloroquine equally affect" exact="tumor" post="necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral"/>
 <result pre="affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by" exact="peripheral" post="blood mononuclear cellsJ. Rheumatol.19972455609002011 66.EwaldS.E.LeeB.L.LauL.WickliffeK.E.ShiG.-P.ChapmanH.A.BartonG.M.The ectodomain of Toll-like receptor"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 71.SchrezenmeierE.DornerT.Mechanisms of action of hydroxychloroquine"/>
 <result pre="Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus"/>
 <result pre="and Block the Entry of Ebola Virus, Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)*J."/>
 <result pre="of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and" exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV)*J. Boil. Chem.20162919218923210.1074/jbc.M116.716100 74.ColsonP.RaoultD.Fighting viruses"/>
 <result pre="Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV)*J. Boil. Chem.20162919218923210.1074/jbc.M116.716100 74.ColsonP.RaoultD.Fighting viruses with"/>
 <result pre="Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV)*J. Boil. Chem.20162919218923210.1074/jbc.M116.716100 74.ColsonP.RaoultD.Fighting viruses with antibiotics:"/>
 <result pre="Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV)*J. Boil. Chem.20162919218923210.1074/jbc.M116.716100 74.ColsonP.RaoultD.Fighting viruses with antibiotics: An"/>
 <result pre="candidate for SARS-CoV-2Science2020eabc193210.1126/science.abc1932 86.Van DoremalenN.LambeT.SpencerA.Belij-RammerstorferS.PurushothamJ.N.PortJ.R.AvanzatoV.BushmakerT.FlaxmanA.UlaszewskaM.et al.ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaquesbioRxiv202010.1101/2020.05.13.093195 87.collab: NIAIDDeveloping Therapeutics and Vaccines for"/>
 <result pre="89.MoxonR.RecheP.A.RappuoliR.Editorial: Reverse VaccinologyFront. Immunol.201910277610.3389/fimmu.2019.0277631849959 90.FierabracciA.The potential of multimer technologies in" exact="type 1" post="diabetes prediction strategiesDiabetes/Metab. Res. Rev.20112721622910.1002/dmrr.116521309048 91.RicciardiM.J.MagnaniD.M.GrifoniA.KwonY.-C.GutmanM.J.GrubaughN.D.GangavarapuK.SharkeyM.SilveiraC.G.T.BaileyV.K.et al.Ontogeny of the"/>
 <result pre="VaccinologyFront. Immunol.201910277610.3389/fimmu.2019.0277631849959 90.FierabracciA.The potential of multimer technologies in type 1" exact="diabetes" post="prediction strategiesDiabetes/Metab. Res. Rev.20112721622910.1002/dmrr.116521309048 91.RicciardiM.J.MagnaniD.M.GrifoniA.KwonY.-C.GutmanM.J.GrubaughN.D.GangavarapuK.SharkeyM.SilveiraC.G.T.BaileyV.K.et al.Ontogeny of the B-"/>
 <result pre="91.RicciardiM.J.MagnaniD.M.GrifoniA.KwonY.-C.GutmanM.J.GrubaughN.D.GangavarapuK.SharkeyM.SilveiraC.G.T.BaileyV.K.et al.Ontogeny of the B- and T-cell response in a" exact="primary" post="Zika virus infection of a dengue-naÃ¯ve individual during the"/>
 <result pre="of the B- and T-cell response in a primary Zika" exact="virus infection" post="of a dengue-naÃ¯ve individual during the 2016 outbreak in"/>
 <result pre="the B- and T-cell response in a primary Zika virus" exact="infection" post="of a dengue-naÃ¯ve individual during the 2016 outbreak in"/>
 <result pre="libraries and human seraEMBO J.1994132236224310.1002/j.1460-2075.1994.tb06501.x7514533 93.EliyahuS.SharabiO.ElmedviS.TimorR.DavidovichA.VigneaultF.ClouserC.HopeR.NimerA.BraunM.et al.Antibody Repertoire Analysis of" exact="Hepatitis" post="C Virus Infections Identifies Immune Signatures Associated With Spontaneous"/>
 <result pre="seraEMBO J.1994132236224310.1002/j.1460-2075.1994.tb06501.x7514533 93.EliyahuS.SharabiO.ElmedviS.TimorR.DavidovichA.VigneaultF.ClouserC.HopeR.NimerA.BraunM.et al.Antibody Repertoire Analysis of Hepatitis C Virus" exact="Infections" post="Identifies Immune Signatures Associated With Spontaneous ClearanceFront. Immunol.20189300410.3389/fimmu.2018.0300430622532 Figure"/>
 <result pre="of Hepatitis C Virus Infections Identifies Immune Signatures Associated With" exact="Spontaneous" post="ClearanceFront. Immunol.20189300410.3389/fimmu.2018.0300430622532 Figure 1 Severe Acute Respiratory Syndrome-Coronavirus 2"/>
 <result pre="Identifies Immune Signatures Associated With Spontaneous ClearanceFront. Immunol.20189300410.3389/fimmu.2018.0300430622532 Figure 1" exact="Severe" post="Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) structure and host cell"/>
 <result pre="Immune Signatures Associated With Spontaneous ClearanceFront. Immunol.20189300410.3389/fimmu.2018.0300430622532 Figure 1 Severe" exact="Acute" post="Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) structure and host cell interaction."/>
 <result pre="Signatures Associated With Spontaneous ClearanceFront. Immunol.20189300410.3389/fimmu.2018.0300430622532 Figure 1 Severe Acute" exact="Respiratory" post="Syndrome-Coronavirus 2 (SARS-CoV2) structure and host cell interaction. ijms-21-05145-t001_Table"/>
 <result pre="cleavage/Inhibition of functional S1 and S2 subunits production [49] RBD-ACE2/BlockingS-protein-mediated" exact="infection" post="[49] RNA synthesis inhibitors (3TC, TDF) [18] Renin-angiotensin system"/>
 <result pre="(3TC, TDF) [18] Renin-angiotensin system (RAS) inhibitors ACE1 and Angiotensin" exact="type 1" post="receptors [54] Antisense RNA (siRNA) Reduction of virus replication"/>
 <result pre="fusion [50,76] Arbidol (Antiviral) Effect on several stages of the" exact="viral" post="life cycle, such as cell entry (attachment, internalization) and"/>
 <result pre="on a lysosomotropic base that appears to disrupt intracellulartrafficking and" exact="viral" post="fusion events [64,70] Teicoplanin(glycopeptide antibiotic) Blocked virus entry by"/>
</results>
